|
Frequency And Clinical Consequences
Of Extremely High Maternal Serum Papp-a Levels
Combined First-trimester Versus Second-trimester
Serum Screening For Down Syndrome: A Cost
Analysis
First Trimester Screening With Free B-hCG,
Papp-a And Nuchal Translucency In Pregnancies
Conceived With Assisted Reproduction
Screening For Aneuploidy Using Material
Blood Spots In The First And Second Trimester.
Evaluation Of Ductus Venosus Blood Flow
As A Screening Marker For Down Syndrome In
The First-trimester.
First-trimester Down Syndrome Screening
In Twins: Moving From "pseudo-risk" To
Real Risk.
First Trimester Biochemical Screening For
Down Syndrome: Free Beta hCG Versus Intact
hCG
First-trimester Down Syndrome Screening
Using Dried Blood Biochemistry And Nuchal
Translucency
Comparison Of Urinary Free Beta (hCG) And
Beta-core (hCG) In Prenatal Screening For
Chromosomal Abnormalities
Urine Free Beta hCG And Beta Core In Pregnancies
Affected By Down's Syndrome
Dimeric Inhibin A As A Marker For Down's
Syndrome In Early Pregnancy
First-trimester Down Syndrome Screening:
Free Beta-human Chorionic Gonadotropin And
Pregnancy-associated Plasma Protein A.
Prenatal Maternal Dried Blood Screening
With Alpha-fetoprotein And Free Beta-human
Chorionic Gonadotropin For Open Neural Tube
Defect And Down Syndrome.
Enhanced Twin Pregnancy Detection Within
An Open Neural Tube Defect And Down Syndrome
Screening Protocol Using Free-beta hCG And
Afp.
|
